Epstein-Barr virus (EBV) is a ubiquitous DNA virus that infects most of the world's population. It is implicated in a multitude of human diseases from frankly malignant, monoclonal disorders, such as Burkitt lymphoma, to borderline malignant, occasionally polyclonal disorders, such as posttransplant lymphoproliferative disorders. Fortunately, the most common pattern of EBV infection is a clinically silent, childhood infection. When primary infection occurs during adolescence or adulthood, EBV may cause infectious mononucleosis (IM), a typically benign, self-limited disorder. Clinically, IM is characterized by fever, pharyngitis, lymphadenopathy, and, often, splenomegaly; morphologically, it is characterized by exuberant, polyclonal lymphoproliferation. In this disorder, EBV infects B lymphocytes, inducing a cytotoxic T-cell response that eventually curbs viral proliferation and restrains the immune response ❚Figure 1❚.
In a small number of patients, however, IM pursues a much more aggressive course: early lymphocytosis in peripheral blood is soon followed by lymphocytic invasion of vital organs, hemophagocytosis, massive marrow necrosis, and severe pancytopenia. [1] [2] [3] [4] [5] Such patients usually die of opportunistic infections and/or hemorrhage within several weeks. 1, 5 The majority of patients with severe or fatal IM (FIM) are immunocompromised, either by an inherited immunodeficiency disorder, such as X-linked lymphoproliferative syndrome, or from administration of immunosuppressive drugs. [6] [7] [8] [9] Thus, they are unable to mount the immunologic response necessary to contain EBV proliferation (Figure 1) . A small number of patients with severe or fatal IM, however, apparently are immunocompetent before EBV infection. Cases of sporadic fatal IM (SFIM) occurring in these patients number approximately 1 in 3,000 cases of IM; in these cases, the factors leading to uncontrolled lymphoproliferation are more difficult to define. 3, 4 We studied 5 previously healthy patients and 1 immunodeficient patient who developed severe or fatal IM. The polymerase chain reaction (PCR) and Southern blot analysis were used to evaluate EBV clonality and immunoglobulin heavy chain (IgH) gene and T-cell receptor (TCR) gene rearrangement status. We also reviewed the morphologic findings in available tissues in each case. Molecular and morphologic findings were correlated with each patient's clinical course, as obtained from medical records.
Materials and Methods

EBV Detection
Two methods were used to detect and characterize EBV within the patient samples: polymerase chain reaction (PCR) and Southern blot analysis.
Polymerase Chain Reaction
DNA was isolated from the specimen through the use of the PureGene System (Gentra Systems, Minneapolis, MN). PCR was performed in a total volume of 50 µL with 2 µL of sample containing 0.15 ng of DNA. Other components of the PCR cocktail included the following: a 0.25-mmol/L concentration of magnesium chloride, a 0.025-mmol/L concentration of each deoxynucleoside triphosphate, and 1 U of AmpliTaq (Applied Biosystems, Foster City, CA). To amplify EBV, a 0.15-mmol/L concentration of an EBV sense primer (5'-GCAGTAACAGGTAATCTCTGG-3') and a 0.15-mmol/L concentration of an EBV antisense primer (5'-CCAGAAATAGCTGCAGGACC-3'), which amplify a 401-base-pair portion of the BamH1 W fragment of EBV, were used. As an internal control, a 0.3-mmol/L concentration of a p53 sense primer (5'-TATCCTGAGTAGTGGTAATC-3') and a 0.3-mmol/L concentration of a p53 antisense primer (5'-AAGTGAATCTGAGGCATAAC-3'), which amplify exon 8 of the p53 gene, were included in each reaction. Each PCR run included an FJO cell line sample as a positive control.
DNA was amplified using the following thermal cycler parameters: 94°C for 3 minutes; 30 cycles of 94°C for 1 minute, 59°C for 30 seconds, and 72°C for 30 seconds; 72°C for 5 minutes; and a 4°C soak. PCR products were electrophoresed on a Novex precast 6% polyacrylamide gel (Novex, San Diego, CA) at 100 V for 1 hour. Products were analyzed after staining the gels in ethidium bromide.
Southern Blot Analysis
Southern blot analysis was performed using a 7.7-kb fused terminal fragment probe. 10 Briefly, 10 µg of sample DNA was digested with the BamH1 restriction endonuclease. The fragments were electrophoresed through a 0.6% agarose gel and transferred to a Zetabind membrane (Cuno, Meriden, CT). The probe was labeled with phosphorus 32 by nick translation. 11 The membrane was hybridized with the probe overnight at 42°C. The membrane was then washed in 2× standard saline citrate and 0.1% sodium dodecyl sulfate for 15 minutes at room temperature, followed by two 30-stringency washes, each with 0.1% standard saline citrate and 0.1% sodium dodecyl sulfate at 60°C.
Gene Rearrangement Detection
Gene rearrangement detection was performed using PCR, followed by Southern BLOT analysis when necessary for confirmation, using methods outlined by Coad et al. 12, 13 
Results
Clinical Findings
Four patients with SFIM, 1 patient with FIM, and 1 patient with sporadic severe IM (SSIM) were included in the study. Patients ranged in age from 26 months to 17 years (mean, 10 years, 10 months). Five of 6 patients were previously healthy, with no known immunodeficiencies or receipt of immunosuppressive therapy. One patient had a history of 
Morphologic Features
Histologic examination was performed in all 6 cases ❚Table 1❚. In 4 of 6 cases, autopsies were performed; in the remaining 2 cases, limited organ biopsies were performed. Three of 4 patients with SFIM (cases 1-3) had remarkably similar histopathologic findings, consisting of the following: (1) polymorphous lymphoid infiltrates, (2) histiocytosis, (3) necrosis, (4) lymphoid depletion, and/or (5) hemophagocytosis. In all 3 patients, these features were widespread. The lymph nodes, spleen, liver, and bone marrow were consistently involved, showing 2 or more of the aforementioned features ❚Image 1❚ through ❚Image 4❚.
Other organs, such as lung, kidneys, and pancreas, showed variable involvement. In the remaining patient with SFIM (case 4), an autopsy was not performed. Liver and lung biopsies for this patient revealed histiocytosis, lymphoid infiltrates, and/or necrosis.
In the patient with SSIM (case 5), morphologic examination of the tonsils revealed a diffuse polymorphous lymphoid infiltrate. However, no histiocytosis, necrosis, lymphocyte depletion, or hemophagocytosis were present.
Finally, in the patient with FIM (case 6), examination of autopsy material revealed widespread, atypical, polymorphous lymphoid infiltrates in virtually all organs examined. Although necrosis was present in a few organs, histiocytosis, lymphocyte depletion, and hemophagocytosis were absent. In each patient, the morphologic abnormalities seemed to be commensurate with the degree of clinical severity. In the 4 cases of SFIM described herein, the morphologic features were similar to those described by others. 1, 4 Notably, most involved organs contained polymorphous lymphoid infiltrates, necrosis, hemophagocytosis, and histiocytosis; occasionally, lymphocyte depletion was present. However, not all features were present in each organ in each case. The morphologic features in the case of FIM occurring in an immunodeficient patient were slightly different; widespread polymorphous, strikingly atypical lymphoid infiltrates, occasionally associated with necrosis, were prominent. In contrast, the patient with SSIM had only polymorphous lymphoid infiltrates, with none of the aforementioned features. 
Molecular Studies
Epstein-Barr Virus
PCR for EBV was performed in all 6 cases; EBV was present in each ❚Image 5❚. Furthermore, in the 5 patients with fatal disease, Southern blot analysis revealed monoclonal EBV in 3 and biclonal EBV in 1 ❚Image 6❚. In the remaining patient, DNA was not present in sufficient quantity to perform Southern blot analysis. Southern blot analysis revealed oligoclonal EBV in the patient with SSIM.
Gene Rearrangements
PCR and Southern blot analysis were performed on tissue specimens from all 6 patients (Table 1 ). All 5 patients with fatal disease had monoclonal gene rearrangements; 2 patients had rearrangements of the TCR beta chain, 1 had rearrangement of the TCR beta and TCR gamma chains, and 2 had rearrangements of the IgH gene ❚Image 7❚. Clonal gene rearrangements were not detected in the patient with SSIM.
Discussion
FIM is associated most frequently with EBV infection of an immunocompromised host. The 3 most common causes of immunocompromise are congenital disorders such as X-linked lymphoproliferative disorder, immunosuppressive therapy, and AIDS. 7, 14 There also is increasing literature describing fatal EBV infection of previously healthy individuals. In both vulnerable and previously healthy patients, the clinical and pathologic features of FIM are similar, with the majority of patients dying of organ invasion by proliferating lymphocytes 3 and/or viral associated hemophagocytic syndrome. 1 Before a report published in 1988, in which EBVcontaining T-cell lymphomas were described, 15 it was generally accepted that EBV demonstrated B-cell lymphotrophism. 16 Indeed, EBV infection of B cells has been documented in processes ranging from benign (eg, lifelong persistence of EBV-transformed B cells in an asymptomatic, previously infected host) to frankly malignant (eg, EBV-associated Burkitt lymphoma). Since the initial report, EBV infection of T cells has been well documented. [17] [18] [19] More recently, EBV infection of T cells has been documented in cases of life-threatening 20 and fatal 21 IM. Molecular studies in cases of SFIM have demonstrated monoclonal IgH rearrangements 22 and/or monoclonality detected by Southern blot analysis of the EBV genome. 23, 24 However, there is an increasing literature describing oligoclonal 25 and monoclonal 26 T-cell proliferations in cases of acute and/or life-threatening IM. The association between life-threatening or fatal IM and abnormal T-cell proliferation has led to the suggestion that atypical T-cell proliferation is responsible for the aggressive nature of SFIM. 23, 27 In many of these studies, however, thorough molecular analyses including TCR, immunoglobulin, and EBV clonality analyses have not been performed. In the series of patients described herein, each of the 4 patients with SFIM demonstrated monoclonality or biclonality as detected with the EBV probe; 3 of these patients also had monoclonal TCR gene rearrangements, while the remaining patient demonstrated a monoclonal IgH rearrangement. The patient with SSIM demonstrated oligoclonality with the EBV probe, and no T-cell or IgH rearrangements were detected. Results from this series of patients suggest that poor outcomes in cases of apparently life-threatening IM are most accurately predicted on a molecular basis by EBV clonality studies and that TCR or IgH gene rearrangement studies alone are inadequate. Currently in our laboratory, we use a 2-step approach for the molecular characterization of SSIM and SFIM. The initial step includes PCR analysis for the detection of EBV sequences and TCR and IgH gene rearrangements; for the cases in which EBV is detected, a second step involving EBV clonality studies by Southern blot analysis is performed. We believe this to be the most efficient approach for the molecular evaluation of these cases. Patients with SFIM often undergo a rapid clinical course that is unresponsive to treatment. There is evidence, as well as speculation, in the literature suggesting that T-cell cytokines are responsible for the viral-associated hemophagocytic syndrome that results in the death of these patients. 28 However, neither the precise molecular mechanisms that are responsible for the progression of acute IM to SFIM nor early markers of aggressive disease have been elucidated. It is likely that a prospective multicenter study involving clinical findings and outcomes, hematologic studies, cytokine studies, and molecular analyses will be required to provide insights into the molecular biology, early definitive diagnosis, and effective treatment of SFIM. Until that time, molecular diagnostics will continue to have an important role in the study of FIM. 
